Merck KGaA's Erbitux fails in colon cancer study
FRANKFURT (Reuters) - Germany's Merck KGaA said on Wednesday that Erbitux, one of its most important drugs, failed to help colon cancer patients after surgery in a late stage trial.
A scheduled interim analysis of the so-called Petacc-8 study, which tested Erbitux in combination with standard chemotherapy as a treatment of colon cancer that has started spreading, showed no improvement in disease-free survival compared with using chemotherapy only.
Merck's Erbitux competes with Amgen Vectibix in the market for certain colorectal cancer treatments and is also approved for treating head and neck cancer.
(Reporting by Ludwig Burger)
- Tweet this
- Share this
- Digg this
- Scots independence polls close, UK's future in the balance |
- Factbox - Scotland's independence vote: How will the results come?
- Scots vote in record numbers, await independence verdict |
- Support for Scottish independence at 46 percent - YouGov poll
- Microsoft lays off 2,100, axes Silicon Valley research